Melanoma, while only accounting for approximately 1% of all skin cancers, is responsible for the majority of skin cancer-related deaths. According to estimates from the American Cancer Society for 2025, it is projected that around 104,960 new cases of melanoma will be diagnosed in the United States, with 60,550 cases in men and 44,410 in women. The mortality rate is also significant, with an estimated 8,430 deaths from melanoma in 2025, including 5,470 men and 2,960 women. These statistics highlight the urgent need to address melanoma.
This article, "Guidelines+ Side-by-Side," provides a thorough comparison of the current clinical practice guidelines established by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the American Academy of Dermatology (AAD). By analyzing these recommendations, the aim of this article is to offer healthcare professionals valuable insights and best practices for evaluating melanoma. This evidence-based approach is intended to enhance health outcomes for individuals affected by this condition.
Titles of Comparison:
| Titles | Melanoma: Cutaneous | Systemic Therapy for Melanoma | Management of Primary Cutaneous Melanoma |
|---|---|---|---|
| Society | National Comprehensive Cancer Network (NCCN) | American Society of Clinical Oncology (ASCO) | American Academy of Dermatology (AAD) |
| Publication Date | January 28, 2025 | August 14, 2023 | November 01, 2018 |
| Objective | Guidelines for diagnosis, staging, and management of cutaneous melanoma across all stages. | Guidelines for systemic therapy of melanoma, including immunotherapy, targeted therapy, and chemotherapy | Guidelines for management of primary cutaneous melanoma, including excision and staging |
| Target Population | Patients with cutaneous melanoma | Patients with advanced or metastatic melanoma | Patients diagnosed with primary cutaneous melanoma |
| Methodology | Evidence-based, expert consensus | Evidence-based, expert consensus | Evidence-based, expert consensus |
| Graded Strength of Recommendations | Yes | Yes | Yes |
| Graded Level of Evidence | Yes | Yes | Yes |
| Systematic Review Conducted | Yes | Yes | Yes |
| Literature Review Conducted | Yes | Yes | Yes |
| COIs & Funding Source(s) Disclosed | Yes | Yes | Yes |
| Full-text | Melanoma: Cutaneous | Systemic Therapy for Melanoma | Management of Primary Cutaneous Melanoma |
| Summary | n/a | Summary | Summary |
Treatment Overview
| Melanoma: Cutaneous | Systemic Therapy for Melanoma | Management of Primary Cutaneous Melanoma | |
|---|---|---|---|
| Scope | Comprehensive guidelines for diagnosis, staging, surgery, adjuvant therapy, and systemic therapy for cutaneous melanoma. | Focuses on systemic therapies for metastatic melanoma. | Focuses on the management of primary cutaneous melanoma. |
| Staging | Emphasizes staging with clinical, pathologic, and molecular markers (e.g., sentinel lymph node biopsy). | Not focused on staging, more on systemic treatments for metastatic disease. | Focuses on accurate staging using Clark level and Breslow depth. |
| Surgical Treatment | Primary treatment is surgical resection, with margins based on tumor thickness (Breslow depth). | Surgery is not the main focus, as it emphasizes systemic treatment for advanced disease. | Surgery is the mainstay for primary melanoma treatment. Recommended margins are based on Breslow depth and tumor thickness. |
| Adjuvant Therapy (High-risk Stage IIB/III) | Immunotherapy: nivolumab, pembrolizumab. Targeted therapy: dabrafenib, trametinib (for BRAF-mutant melanomas). | Immunotherapy options: pembrolizumab, nivolumab. BRAF-targeted therapy: vemurafenib, dabrafenib. | Immunotherapy: nivolumab, pembrolizumab. BRAF-targeted therapy for BRAF-mutant cases. |
| Adjuvant Therapy (Stage IV/M stage) | Use of immunotherapy (nivolumab, pembrolizumab) and targeted therapies (BRAF/MEK inhibitors) for resectable and unresectable metastatic melanoma. | Immunotherapy (nivolumab, pembrolizumab) and combination therapies (nivolumab + ipilimumab). BRAF-targeted therapy. | For Stage IV, consider immune checkpoint inhibitors or targeted therapy (BRAF/MEK inhibitors) based on genetic markers. |
| Neoadjuvant Therapy | Recent inclusion of neoadjuvant immunotherapy (nivolumab, pembrolizumab) and neoadjuvant targeted therapy for high-risk melanoma. | Neoadjuvant therapy is still under investigation but includes clinical trials with immunotherapy and targeted therapies. | Not typically addressed in these guidelines. Focus on surgical management. |
| Systemic Therapy for Metastatic Disease | Immunotherapy (nivolumab, pembrolizumab), targeted therapies (BRAF/MEK inhibitors), chemotherapy (dacarbazine, temozolomide) for select cases. | Focus on immunotherapy (nivolumab, pembrolizumab) and BRAF-targeted therapy for BRAF-mutant melanoma (vemurafenib, dabrafenib). | Focus on immunotherapies for advanced stages, including nivolumab, pembrolizumab, and BRAF inhibitors for BRAF-positive tumors. |
| Chemotherapy | Chemotherapy is less emphasized for metastatic melanoma but may still be considered in certain cases (dacarbazine, temozolomide). | Limited use of chemotherapy, primarily considered when targeted therapy and immunotherapy fail. | Chemotherapy is a less preferred option compared to immunotherapies or targeted therapies. |
| Radiotherapy | Used for palliation in metastatic melanoma, or in specific scenarios like brain metastases or unresectable lesions. | Mentioned for symptomatic or palliative care in advanced/metastatic melanoma. | Considered for local control in unresectable lesions or as an adjuvant treatment in select cases. |
| Follow-Up | Regular follow-up with clinical exams, imaging, and laboratory tests, especially for high-risk patients or those treated with adjuvant therapy. | Follow-up is emphasized to monitor treatment efficacy, adverse effects, and progression in metastatic melanoma. | Follow-up after surgery to detect recurrence is recommended, typically through clinical examination and imaging for high-risk cases. |
| Targeted Therapy (BRAF/MEK Inhibitors) | For BRAF-mutant melanoma, combination therapy with BRAF inhibitors (dabrafenib) and MEK inhibitors (trametinib). | BRAF/MEK inhibitors (e.g., vemurafenib, dabrafenib) are recommended for BRAF-mutant metastatic melanoma. | BRAF/MEK inhibitors are a key treatment for BRAF-positive tumors, especially in metastatic or high-risk cases. |
| Immune Checkpoint Inhibitors | Nivolumab and pembrolizumab are recommended as adjuvant and systemic treatments for both resectable and metastatic melanoma. | Nivolumab, pembrolizumab, and combination therapies (nivolumab + ipilimumab) for advanced melanoma. | Nivolumab, pembrolizumab, and ipilimumab are recommended for high-risk and advanced cases. |
| Special Populations | Tailors treatment recommendations for elderly, immunocompromised, and patients with specific genetic mutations (BRAF, NRAS). | Special considerations for patients with comorbidities or those who are not candidates for systemic therapy. | Focuses on patients with primary cutaneous melanoma but may adjust for age or other comorbidities. |
| Special Considerations | Includes considerations for patients with specific genetic mutations (e.g., BRAF mutations), elderly patients, and those with comorbidities. | Focuses on optimizing systemic therapy for patients with metastatic melanoma, emphasizing efficacy and tolerability. | Guidelines focus on the importance of molecular markers and tailoring treatment based on risk factors. |
Key Takeaways
- Scope of Guidelines
- NCCN provides comprehensive guidance on all stages of melanoma, including diagnosis, surgery, and systemic therapy; ASCO focuses on systemic therapies for metastatic melanoma, and AAD targets primary cutaneous melanoma and surgical management.
- Staging and Surgery
- NCCN emphasizes detailed staging (clinical, pathologic, molecular) and surgical resection with margins based on Breslow depth; ASCO does not focus on staging but emphasizes systemic treatments, while AAD focuses on accurate staging and surgical management for primary melanoma.
- Adjuvant and Systemic Therapy
- All guidelines include immunotherapy (nivolumab, pembrolizumab) and BRAF-targeted therapy for high-risk or metastatic melanoma, with ASCO emphasizing combination immunotherapy for advanced stages and NCCN incorporating neoadjuvant therapies.
- Chemotherapy
- Chemotherapy is less emphasized across all guidelines for advanced melanoma but may still be used selectively (dacarbazine, temozolomide) when other therapies fail.
- Follow-Up
- Follow-up recommendations vary, with NCCN focusing on regular clinical exams and imaging for high-risk patients, ASCO monitoring treatment efficacy for metastatic cases, and AAD recommending follow-up for recurrence detection after surgery.
- Special Considerations
- NCCN and AAD provide tailored recommendations for elderly, immunocompromised, and genetically predisposed populations (e.g., BRAF mutations), while ASCO emphasizes managing patients with comorbidities or those unsuitable for systemic therapy.
In conclusion, the guidelines for melanoma treatment provided by the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and American Academy of Dermatology (AAD) offer valuable insights into effectively managing various stages and aspects of melanoma. Each guideline focuses on distinct areas, providing a comprehensive approach to treatment. All three guidelines acknowledge the importance of immunotherapy and targeted therapies, especially in cases of high-risk or metastatic melanoma. However, they differ in their scope and emphasis. The NCCN guidelines offer a broader framework for treatment, while ASCO focuses on advanced-stage melanoma treatment, and AAD prioritizes surgical intervention for primary melanomas.
Overall, these guidelines reflect the evolving understanding of melanoma management, emphasizing the importance of balancing surgical interventions, systemic treatments, and personalized care to cater to the diverse needs of different patient populations.
Make sure to sign up for guideline alerts to stay up to date on all future side-by-side blogs and let us know if there is a topic you’d like to see compared on our next article!
Copyright © 2025 Guideline Central, All Rights Reserved.